Peptide · Fact sheet
Liraglutide
Also known as Victoza · Saxenda
Liraglutide is FDA approved in products for type 2 diabetes and chronic weight management. Approval and age criteria depend on the exact product label.
What is Liraglutide?
Liraglutide is a manufactured GLP-1 analog. It acts on a receptor involved in blood-sugar regulation, appetite, and digestion.
Victoza and Saxenda contain liraglutide but have different labeled uses and should not be treated as a single generic claim.
Benefits people look for
Liraglutide has a longer clinical history than several other incretin medicines.
Readers often compare its evidence, schedule, outcomes, and risks with semaglutide and tirzepatide.
What the evidence supports
- Controlled trials support benefits for blood-sugar control and chronic weight management in labeled populations.
- The amount and type of benefit differ by population, endpoint, and product indication.
All research areas
- Type 2 diabetes
- Chronic weight management
- Cardiovascular outcomes
- Other metabolic outcomes outside current labels
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Gastrointestinal effects such as nausea, diarrhea, constipation, and vomiting are common.
- Labels include a boxed warning related to thyroid C-cell tumors in rodents and list important contraindications.
- Other concerns can include pancreatitis, gallbladder disease, kidney problems related to dehydration, and low blood sugar with certain other medicines.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesLarge clinical programs support approved uses, including cardiovascular outcomes evidence in a labeled diabetes population.
Selected research to read
Registry record for the liraglutide cardiovascular outcomes trial.
Peer-reviewed report of a large liraglutide cardiovascular outcomes trial.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| LEADER Type 2 diabetes and high cardiovascular risk 9,340 participants (actual) Randomized placebo-controlled trial; human | Liraglutide versus Placebo Median follow-up 3.8 years Primary: First cardiovascular death, nonfatal heart attack or nonfatal stroke Phase: Not listed in this summary | 608/4668 (13.0%) versus 694/4672 (14.9%) had a primary event. 1.9 percentage points fewer events, using rounded published proportions. Hazard ratio 0.87; 95% CI 0.78–0.97. Cannot tell us: Population differs from SELECT; these two placebo comparisons cannot rank liraglutide against semaglutide. Safety, uncertainty, and source detailsGastrointestinal events most commonly led to discontinuation. Limited to the studied population, formulation and follow-up. Funding/conflicts: Novo Nordisk and NIH; individual disclosures not fully extracted. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
Who was studied in LEADER?
Reduced composite cardiovascular events in adults with type 2 diabetes and high cardiovascular risk.
Limit: The trial does not answer the same population question as SELECT.
Check the sources: LEADER: liraglutide cardiovascular outcomes (checked 2026-09-18) · FDA Victoza prescribing information (checked 2026-09-18)
What is approved, and for whom?
United States records selected for the questions above; not a complete label or a worldwide approval inventory.
Victoza: Cardiovascular outcomes
Subcutaneous injection · Adults with type 2 diabetes and established cardiovascular disease
approved — Does not transfer to people without diabetes or establish general longevity benefit.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Compare research questions · Submit a source-based correction
FDA approval & research status
FDA-approved liraglutide products have indications for type 2 diabetes or chronic weight management in defined populations. Check current labeling for age and eligibility details.
Approved uses covered here
- Improving blood sugar control in specified people with type 2 diabetes
- Chronic weight management in specified adults and adolescents
- Reducing specified cardiovascular risks under the applicable label
FDA approved for labeled products
FDA labels cover liraglutide products for specific diabetes and chronic-weight-management uses. The exact indication, age range, and risk language depend on the product.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- How outcomes compare directly across related medicines and populations
- Whether research outside approved uses will produce meaningful clinical benefits
- Individual benefit-risk tradeoffs that require a clinician's review
The takeaway
Liraglutide is an established prescription medicine, but its evidence should be discussed by product, labeled use, population, and individual risks—not by class reputation alone.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Victoza
Official prescribing information for a liraglutide type 2 diabetes product.
- 2
- 3clinical trialsClinicalTrials.gov: LEADER cardiovascular outcomes trial
Registry record for the liraglutide cardiovascular outcomes trial.
- 4pubmedLEADER liraglutide cardiovascular outcomes trial
Peer-reviewed report of a large liraglutide cardiovascular outcomes trial.